Humana's $1.26 Billion Volume Surge Propels It to 174th Rank in Equity Trading Activity

On September 19, 2025, , . , ranking 174th in volume among listed equities.

Recent developments indicate shifting dynamics in the healthcare sector. A strategic partnership between Humana and a major pharmaceutical firm to expand prescription drug coverage has drawn investor scrutiny. While the collaboration aims to reduce member out-of-pocket costs, analysts highlight potential margin pressures from negotiated pricing concessions. Separately, , signaling competitive challenges in its core markets.

Market participants are also monitoring . A pending federal investigation into industry-wide pricing practices has sparked sector-wide volatility. Though Humana has not been directly implicated, its stock price has tracked broader healthcare sector corrections as investors reassess risk exposure. The company’s recent capital allocation strategy, , remains under evaluation for its impact on long-term shareholder value.

To run this back-test accurately I need to confirm a few practical details: 1. Universe • Are we looking at all common stocks listed on NYSE + NASDAQ (≈ 6 000 names) or a narrower set (e.g., S&P 1500)? 2. Trade timing • Buy at today’s close and liquidate at tomorrow’s close, or buy at tomorrow’s open and liquidate at tomorrow’s close? • Use split-adjusted “close” prices for P&L, or “open” prices? 3. Transaction costs & slippage • Should we include an estimate (e.g., 2 bp per side) or assume frictionless trading? 4. Cash handling • Equal-weight across the 500 names each day, fully invested, with overnight cash earning zero? If the default in each case (full US stock universe, close-to-close returns, no costs, equal-weight, zero cash return) is acceptable, just let me know and I’ll proceed with those assumptions.